药品注册申请号:013174
申请类型:NDA (新药申请)
申请人:CONCORDIA
申请人全名:CONCORDIA PHARMACEUTICALS INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 DYRENIUM TRIAMTERENE CAPSULE;ORAL 50MG Yes No AB 1964/08/10 Approved Prior to Jan 1, 1982 Prescription
002 DYRENIUM TRIAMTERENE CAPSULE;ORAL 100MG Yes Yes AB Approved Prior to Jan 1, 1982 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2002/02/28 SUPPL-59(补充) Approval Manufacturing (CMC) PRIORITY
1994/09/13 SUPPL-58(补充) Approval Labeling STANDARD
1992/12/09 SUPPL-57(补充) Approval Manufacturing (CMC) PRIORITY
1992/06/03 SUPPL-56(补充) Approval Manufacturing (CMC) PRIORITY
1990/03/07 SUPPL-54(补充) Approval Labeling
1988/11/09 SUPPL-53(补充) Approval Labeling
1988/02/02 SUPPL-52(补充) Approval Manufacturing (CMC) PRIORITY
1987/09/29 SUPPL-51(补充) Approval Labeling
1987/09/23 SUPPL-50(补充) Approval Manufacturing (CMC) PRIORITY
1985/10/04 SUPPL-45(补充) Approval Labeling
1982/08/25 SUPPL-46(补充) Approval Labeling
1981/02/05 SUPPL-40(补充) Approval Manufacturing (CMC) PRIORITY
1980/07/14 SUPPL-44(补充) Approval Labeling
1979/11/26 SUPPL-43(补充) Approval Labeling
1979/11/12 SUPPL-41(补充) Approval Labeling
1979/08/07 SUPPL-39(补充) Approval Labeling
1978/11/16 SUPPL-37(补充) Approval Labeling
1978/08/15 SUPPL-36(补充) Approval Labeling
1978/05/22 SUPPL-30(补充) Approval Labeling
1978/05/22 SUPPL-29(补充) Approval Labeling
1978/02/17 SUPPL-31(补充) Approval Labeling
1978/01/19 SUPPL-34(补充) Approval Manufacturing (CMC) PRIORITY
1978/01/19 SUPPL-33(补充) Approval Manufacturing (CMC) PRIORITY
1978/01/19 SUPPL-32(补充) Approval Manufacturing (CMC) PRIORITY
1977/12/12 SUPPL-35(补充) Approval Manufacturing (CMC) PRIORITY
1977/04/01 SUPPL-26(补充) Approval Labeling
1977/02/14 SUPPL-28(补充) Approval Manufacturing (CMC) PRIORITY
1977/02/14 SUPPL-27(补充) Approval Manufacturing (CMC) PRIORITY
1976/11/05 SUPPL-24(补充) Approval Labeling
1976/09/03 SUPPL-23(补充) Approval Labeling
1976/09/03 SUPPL-22(补充) Approval Labeling
1976/09/03 SUPPL-20(补充) Approval Labeling
1976/01/14 SUPPL-21(补充) Approval Manufacturing (CMC) PRIORITY
1976/01/14 SUPPL-19(补充) Approval Labeling
1976/01/14 SUPPL-16(补充) Approval REMS PRIORITY
1975/07/24 SUPPL-14(补充) Approval REMS PRIORITY
1975/06/02 SUPPL-18(补充) Approval Manufacturing (CMC) PRIORITY
1975/06/02 SUPPL-17(补充) Approval Labeling
1975/06/02 SUPPL-11(补充) Approval REMS PRIORITY
1964/08/10 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:TRIAMTERENE 剂型/给药途径:CAPSULE;ORAL 规格:50MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
013174 001 NDA DYRENIUM TRIAMTERENE CAPSULE;ORAL 50MG Prescription Yes No AB Approved Prior to Jan 1, 1982 CONCORDIA
211581 001 ANDA TRIAMTERENE TRIAMTERENE CAPSULE;ORAL 50MG Prescription No No AB 2019/08/19 AGNITIO
214768 001 ANDA TRIAMTERENE TRIAMTERENE CAPSULE;ORAL 50MG Prescription No No AB 2022/07/06 BIOCON GENERICS
活性成分:TRIAMTERENE 剂型/给药途径:CAPSULE;ORAL 规格:100MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
013174 002 NDA DYRENIUM TRIAMTERENE CAPSULE;ORAL 100MG Prescription Yes Yes AB Approved Prior to Jan 1, 1982 CONCORDIA
211581 002 ANDA TRIAMTERENE TRIAMTERENE CAPSULE;ORAL 100MG Prescription No No AB 2019/08/19 AGNITIO
214768 002 ANDA TRIAMTERENE TRIAMTERENE CAPSULE;ORAL 100MG Prescription No No AB 2022/07/06 BIOCON GENERICS
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database